End-of-day quote
Egyptian Exchange
06:00:00 2024-05-15 pm EDT
|
5-day change
|
1st Jan Change
|
28.31
EGP
|
+2.57%
|
|
-6.04%
|
-20.37%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,650
|
1,650
|
1,416
|
2,579
|
3,187
|
2,969
|
Enterprise Value (EV)
1 |
1,344
|
1,634
|
1,540
|
2,685
|
2,671
|
2,237
|
P/E ratio
|
-
|
11.6
x
|
50.4
x
|
16.7
x
|
4.33
x
|
49.1
x
|
Yield
|
-
|
-
|
-
|
2.43%
|
-
|
2.11%
|
Capitalization / Revenue
|
1.02
x
|
0.97
x
|
0.71
x
|
1.42
x
|
1.75
x
|
1.33
x
|
EV / Revenue
|
0.83
x
|
0.96
x
|
0.77
x
|
1.48
x
|
1.46
x
|
1
x
|
EV / EBITDA
|
9.85
x
|
5.68
x
|
6.67
x
|
9.65
x
|
55
x
|
4.7
x
|
EV / FCF
|
8.25
x
|
-5.54
x
|
16.1
x
|
54.1
x
|
24.6
x
|
12.8
x
|
FCF Yield
|
12.1%
|
-18%
|
6.22%
|
1.85%
|
4.06%
|
7.79%
|
Price to Book
|
-
|
1.36
x
|
1.17
x
|
1.9
x
|
1.84
x
|
1.51
x
|
Nbr of stocks (in thousands)
|
83,514
|
83,514
|
83,514
|
83,514
|
83,514
|
83,514
|
Reference price
2 |
-
|
19.76
|
16.96
|
30.88
|
38.16
|
35.55
|
Announcement Date
|
9/26/19
|
5/1/20
|
5/30/22
|
5/30/22
|
3/18/24
|
3/18/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,623
|
1,704
|
1,993
|
1,812
|
1,823
|
2,240
|
EBITDA
1 |
136.4
|
287.9
|
230.9
|
278.3
|
48.6
|
475.6
|
EBIT
1 |
110.1
|
267.6
|
202.5
|
242.2
|
15.33
|
441.5
|
Operating Margin
|
6.79%
|
15.7%
|
10.16%
|
13.36%
|
0.84%
|
19.71%
|
Earnings before Tax (EBT)
1 |
66.48
|
197.2
|
91.9
|
179.4
|
-62.94
|
119.7
|
Net income
1 |
49.92
|
142.6
|
28.13
|
154.6
|
735.4
|
60.46
|
Net margin
|
3.07%
|
8.37%
|
1.41%
|
8.53%
|
40.33%
|
2.7%
|
EPS
2 |
0.4075
|
1.708
|
0.3368
|
1.852
|
8.805
|
0.7239
|
Free Cash Flow
1 |
162.8
|
-294.8
|
95.72
|
49.65
|
108.4
|
174.2
|
FCF margin
|
10.03%
|
-17.3%
|
4.8%
|
2.74%
|
5.94%
|
7.78%
|
FCF Conversion (EBITDA)
|
119.34%
|
-
|
41.45%
|
17.84%
|
222.99%
|
36.63%
|
FCF Conversion (Net income)
|
326.18%
|
-
|
340.25%
|
32.11%
|
14.74%
|
288.14%
|
Dividend per Share
2 |
0.5000
|
-
|
-
|
0.7500
|
-
|
0.7500
|
Announcement Date
|
9/26/19
|
5/1/20
|
5/30/22
|
5/30/22
|
3/18/24
|
3/18/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
124
|
106
|
-
|
-
|
Net Cash position
1 |
307
|
16
|
-
|
-
|
516
|
732
|
Leverage (Debt/EBITDA)
|
-
|
-
|
0.5352
x
|
0.3823
x
|
-
|
-
|
Free Cash Flow
1 |
163
|
-295
|
95.7
|
49.7
|
108
|
174
|
ROE (net income / shareholders' equity)
|
4.69%
|
12.4%
|
2.32%
|
12%
|
-7.38%
|
3.27%
|
ROA (Net income/ Total Assets)
|
3.5%
|
7.58%
|
5.62%
|
6.66%
|
0.34%
|
8.18%
|
Assets
1 |
1,426
|
1,881
|
500.5
|
2,320
|
215,401
|
738.7
|
Book Value Per Share
2 |
12.90
|
14.60
|
14.50
|
16.30
|
20.70
|
23.50
|
Cash Flow per Share
2 |
3.670
|
3.010
|
0.2700
|
0.8800
|
7.010
|
9.930
|
Capex
1 |
84.6
|
133
|
53.7
|
35.8
|
48.8
|
77.1
|
Capex / Sales
|
5.21%
|
7.81%
|
2.69%
|
1.97%
|
2.67%
|
3.44%
|
Announcement Date
|
9/26/19
|
5/1/20
|
5/30/22
|
5/30/22
|
3/18/24
|
3/18/24
|
|
1st Jan change
|
Capi.
|
---|
| -20.37% | 50.4M | | +32.09% | 693B | | +29.39% | 584B | | -1.34% | 372B | | +20.34% | 332B | | +7.39% | 294B | | +14.25% | 239B | | -3.03% | 211B | | +10.02% | 210B | | +8.49% | 168B |
Other Pharmaceuticals
|